Leading specialty therapy drugs in the U.S. by PMPY spending 2016
This statistic shows the leading specialty therapeutic drugs in the United States in 2016, based on per-member-per-year spending. Humira Pen (adalimumab) for inflammatory conditions had the highest PMPY spending, reaching over 45 U.S. dollars in that year.